NCT01282047View on ClinicalTrials.gov

Lenalidomide in Kaposi Disease Associated With HIV Infection

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

HIV Infection Associated Kaposi Disease

Interventions

DRUG

Lenalidomide

oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.

Trial Locations (1)

92141

Valerie Martinez, Clamart